Par Pharmaceutical
Companies, Inc. today announced that its Par Pharmaceutical, Inc. operating
subsidiary has entered into an exclusive U.S. supply and distribution
agreement with AstraZeneca AZN to distribute the authorized generic version of
AstraZeneca's Atacand HCT^® (candesartan cilexetil/hydrochlorothiazide). Par
has begun shipping 16/12.5 mg, 32/12.5 mg and 32/25 mg strengths of
candesartan cilexetil/ hydrochlorothiazide tablets. According to IMS Health
data, annual U.S. sales of Atacand HCT^® are approximately $61 million.
Market News and Data brought to you by Benzinga APIs© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Loading...
Posted In: News
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in